Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Parent Project Muscular Dystrophy | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Longitudinal prospective observational study. This is a 24-month study with the possibility of extending the data time points. Initially baseline, then 12 and 24 months follow up studies will be completed.
Four cohorts are enrolled in this study. The target population is the cohort of genetically confirmed DMD/BMD female carriers (Cohort A). This cohort will consist of 150 DMD/BMD mothers who are somatic carriers of a mutation in the DMD gene. The data collected for this cohort will be compared to three control groups; Control Group B is a cohort of 50 DMD/BMD mothers who are NOT somatic carriers, Control Group C is a cohort of 50 age-matched healthy controls and Control Group D is a cohort of 25 genetically confirmed carriers who do not have an affected child. The inclusion of a Control Group B allows for a comparison to a group of mothers that share the emotional and cognitive burden of caring for an affected male without having the physical or cognitive risks of being a female carrier. The Control Group C offers robust data from an age-matched healthy cohort for purposes of comparison. Control Group D allows for comparison to a group of women that have the same physical or cognitive risks as the Cohort A female carriers, but do not have the same burden of care giving.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort A | DMD/BMD Female Carriers who have/had an affected child (n=150) |
| |
| Cohort B | DMD/BMD Female non-carriers controls who have/had an affected child (n=50) |
| |
| Cohort C | Healthy Age-Matched Controls (n=50) |
| |
| Cohort D | DMD/BMD Female Carriers with no affected children (n=25) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Genetic characterization | Genetic | Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts |
|
| Measure | Description | Time Frame |
|---|---|---|
| Compromise of cardiac function based on Cardiac Magnetic Resonance Imaging | Cardiac function as compromised by evidence of scarring of cardiac muscles, particularly of the base of the left ventricle via cardiac MRI studies with gadolinium contrast. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac Function Assessment Treadmill SVO2 | Stress on heart muscle measured by SVO2 (percentage of oxygen saturation in the blood of the pulmonary artery). SVO2 represents an average of all the venous oxygen saturation of major organs and tissues. This measure provides assessment of cardiopulmonary function and helps measure the degree of cardiac instability and can be an indicator of deterioration from normal. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Cohort A: DMD/BMD Female Carriers who have/had an affected child (n=150) Cohort B: DMD/BMD Female non-carriers controls who have/had an affected child (n=50) Cohort C: Healthy Age-Matched Controls (n=50) Cohort D: DMD/BMD Female Carriers who do not have/had an affected child (n=25)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| May Ling Mah, MD | PI | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nationwide Children's Hosptial | Columbus | Ohio | 43205 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32473283 | Derived | Mah ML, Cripe L, Slawinski MK, Al-Zaidy SA, Camino E, Lehman KJ, Jackson JL, Iammarino M, Miller N, Mendell JR, Hor KN. Duchenne and Becker muscular dystrophy carriers: Evidence of cardiomyopathy by exercise and cardiac MRI testing. Int J Cardiol. 2020 Oct 1;316:257-265. doi: 10.1016/j.ijcard.2020.05.052. Epub 2020 May 27. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020388 | Muscular Dystrophy, Duchenne |
| ID | Term |
|---|---|
| D009136 | Muscular Dystrophies |
| D020966 | Muscular Disorders, Atrophic |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
The blood sample for genetic testing will be delivered to the Molecular Genetics lab at Nationwide Children's Hospital, where genomic DNA will be isolated from peripheral white blood cells. DNA will be banked frozen while a portion of the sample will be delivered to the Emory Molecular Genetics Laboratories for testing of the DMD gene.
| 2 years |
| Physical Therapy Assessments Maximum Voluntary Isometric Contraction Testing | MVICT measures strength of skeletal muscles by assessing the force generated by by individual muscles. The results can be compared to norms and deterioration can be assessed over time. | 2 Years |
| Physical Therapy Assessments 6 Minute Walk Test | A timed test to assess distance walked in 6 minutes is very quantitative and can be assessed in comparison to normal controls. Deterioration over time can be clearly measured. | 2 years |
| Physical Therapy Assessments ACTIVE-seated | Exploratory outcome quantifying upper extremity reaching ability using a custom-designed game telling how far the arm reaches in comparison to overall functional ability of the individual ability. | 2 Years |
| Physical Therapy Assessments Time-to-Rise | A timed-test to measure ability to rise from the floor is quantifiable and measuring over time tells if there is loss of function. | 2 Years |
| Laboratory biomarkers - Creatine Kinase | CK levels are an indicator of muscle breakdown. | 2 Years |
| Laboratory biomarkers - C-Reactive Protein | Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown. | 2 Years |
| Laboratory biomarkers - Interleukin-6 | Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown. | 2 Years |
| Laboratory biomarkers - Cortisol levels | Hair cortisol levels measure stress levels as a means of understanding coping with disease. | 2 Years |
| Cognitive Assessment | Cognitive function measured by Wechsler Abbreviated Scale of Intelligence (WASI) provides a possible tool to measure disease awareness and establish if IQ level correlates with disease-related stress. | 2 Years |
| Caregiver Stress | Online self-report survey to assess stress burden on caregiver. | 2 Years |
| Pulmonary function testing (PFTs) | Stable or improved FVC | 2 Years |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D040181 | Genetic Diseases, X-Linked |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |